← Back to Search

Pre-treatment tumour oxygen measurements (under anesthesia) for Cervical Cancer

Phase 2

Waitlist Available

Led By Anthony Fyles, MD

Research Sponsored by University Health Network, Toronto

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Newly diagnosed patients with carcinoma of the cervix ( 3 cm in size or larger) where an examination under anesthesia is to be performed for staging purposes

Informed consent

Timeline

Screening 3 weeks

Treatment Varies

Follow Up follow-up every 3 months for 2 years; every 4-6 months during year 3 to 5; and annually thereafter

Awards & highlights

Study Summary

This trial is measuring oxygen and fluid pressure in the cervix of cancer patients to see if it affects treatment options.

Who is the study for?

This trial is for individuals newly diagnosed with cervical cancer, specifically those with tumors 3 cm or larger. Participants must be undergoing an examination under anesthesia for staging and must provide informed consent to partake in the study.Check my eligibility

What is being tested?

The study aims to measure oxygen levels and interstitial fluid pressure inside cervical cancer tumors. These measurements are taken before any treatment starts, as they may affect how well radiotherapy and other treatments work.See study design

What are the potential side effects?

Since this trial involves measurement procedures rather than drug interventions, side effects are related to the risks of anesthesia and potential discomfort from the measuring process itself.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ tumour measurement will be done 2-3 months following completion of treatment; follow-up every 3 months for 2 years; every 4-6 months during year 3 to 5; and annually thereafter

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~tumour measurement will be done 2-3 months following completion of treatment; follow-up every 3 months for 2 years; every 4-6 months during year 3 to 5; and annually thereafter

This trial's timeline: 3 weeks for screening, Varies for treatment, and tumour measurement will be done 2-3 months following completion of treatment; follow-up every 3 months for 2 years; every 4-6 months during year 3 to 5; and annually thereafter for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

To correlate tumour IFP measured before and during radiation therapy with oxygen tension as measured by the Eppendorf probe and to assess IFP as a prognostic factor for pelvic control.

To determine if tumour oxygen tension prior to and during radiation therapy is an independent prognostic factor for primary tumour response and control in patients with cervix cancer.

Secondary outcome measures

To determine if whole cell or nuclear GSH levels are correlated with tumour oxygen tension and with tumour response and control.